Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Personalised cancer therapy - BriaCell Therapeutics

X
Drug Profile

Personalised cancer therapy - BriaCell Therapeutics

Alternative Names: Bria-APTC; Bria-OTS; Bria-OTS 2.0

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BriaCell Therapeutics Corp
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Dendritic cell stimulants; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 30 May 2024 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy) (Intradermal)
  • 10 Apr 2024 Pharmacodynamics data from a preclinical trial in Breast cancer released by BriaCell Therapeutics
  • 07 Mar 2024 BriaCell Therapeutics enters into an agreement with The University of Texas MD Anderson Cancer Center for personalised cancer therapy and personalised prostate cancer therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top